



212321

00-000000000

This fax machine is located in a secure location as required by HIPAA regulations. Fax complete signed and dated forms to CVS/Caremark at . Please contact CVS/Caremark at 1-888-413-2723 with questions regarding the prior authorization process. When conditions are met, we will authorize the coverage of the medication.

Patient Name: Patient ID:			_ Date: _ Patient Date Of Birth:	10/11/2024				
	ient Group No:	NPI#:	Patient Phone:	Physician Name: Specialty: Physician Office Telephone				
Phy	sician Office Address:						<u> </u>	
Dru	g Name (specify drug)	<del></del>		-				
	antity:							
			<ul><li>Expected Length of Therapy:</li><li>ICD Code:</li></ul>					
Con								
		e answer for each applica	ble question.					
1.	What is the diagnosis? Phenylketonuria (PKL	J) (If checked, go to 2)						
	Other, please specify. (If checked, no further questions)							
2.	600 micromol/L or a gen phenylalanine (Phe) con	rmed by a blood phenylalan netic test? ACTION REQUIR neentration test result or gen Submit supporting docume	ine (Phe) concentration greater than RED: If Yes, please attach blood etic test result. ntation	Y		N		
3.	Is the request for continu	uation of therapy with the re-	quested medication?	Y		N		
4.	Is the patient currently remanufacturer's patient a	eceiving the requested produstions:	uct through samples or a					
	Yes (If checked, go to	10)						
	No (If checked, go to	5)						
	Unknown (If checked,	go to 10)						
5.	Has the patient achieved concentration of less that	d a clinical response as evid an or equal to 600 micromol/	lenced by a blood phenylalanine (Phe) /L?	Y		N		
6.	Will the requested medic	cation be used concomitantl	y with Kuvan for phenylketonuria?	Y		N		
7.	Has the patient been titr	ated to the maximum allowe	ed dose of 60 mg once daily?	Y		N		
8.	Has the patient received 16 weeks or more at the	d continuous treatment with the maximum allowed dose of	the requested medication for at least 60 mg once daily?	Y		N		
9.	Will the requested medic	cation be used concomitantl	y with Kuvan for phenylketonuria?	Y		N		
10.	Prior to initiation of the rephenylalanine (Phe) con	equested medication, what vacentration?	was the patient's baseline blood					
	Greater than 600 mici	romol/L (If checked, go to 11	1)					
	600 micromol/L or les	s (If checked, no further que	estions)					

	No baseline blood Phe concentration (If checked, no further questions)				
11.	Will the requested medication be initiated in a patient currently receiving Kuvan for phenylketonuria (PKU)?	Y		N	
12.	Will Kuvan be discontinued after an appropriate period of overlap?	Y		N	
and tr	It that the medication requested is medically necessary for this patient. I further attest that the information ue, and that the documentation supporting this information is available for review if requested by the clai ponsor, or, if applicable a state or federal regulatory agency.	n pro ms pi	vided is rocessor	accurat , the he	e ealth

Prescriber (Or Authorized) Signature and Date

Now you can get responses to drug PAs immediately and securely online—without faxes, phone calls, or waiting. How? With electronic prior authorization (ePA)! For more information and to register, go to www.caremark.com/epa.